Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

142 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Brighton Collaboration standardized template with key considerations for a benefit-risk assessment for the Comirnaty COVID-19 mRNA vaccine.
Pather S, Charpentier N, van den Ouweland F, Rizzi R, Finlayson A, Salisch N, Muik A, Lindemann C, Khanim R, Abduljawad S, Smith ER, Gurwith M, Chen RT; Benefit-Risk Assessment of VAccines by TechnolOgy Working Group (BRAVATO; ex-V3SWG). Pather S, et al. Among authors: gurwith m. Vaccine. 2024 Sep 17;42(22):126165. doi: 10.1016/j.vaccine.2024.126165. Epub 2024 Aug 27. Vaccine. 2024. PMID: 39197299 Free article. Review.
Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment.
Monath TP, Seligman SJ, Robertson JS, Guy B, Hayes EB, Condit RC, Excler JL, Mac LM, Carbery B, Chen RT; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). Monath TP, et al. Vaccine. 2015 Jan 1;33(1):62-72. doi: 10.1016/j.vaccine.2014.10.004. Epub 2014 Oct 27. Vaccine. 2015. PMID: 25446819 Free PMC article. Review.
Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data.
Sejvar JJ, Kohl KS, Gidudu J, Amato A, Bakshi N, Baxter R, Burwen DR, Cornblath DR, Cleerbout J, Edwards KM, Heininger U, Hughes R, Khuri-Bulos N, Korinthenberg R, Law BJ, Munro U, Maltezou HC, Nell P, Oleske J, Sparks R, Velentgas P, Vermeer P, Wiznitzer M; Brighton Collaboration GBS Working Group. Sejvar JJ, et al. Vaccine. 2011 Jan 10;29(3):599-612. doi: 10.1016/j.vaccine.2010.06.003. Epub 2010 Jun 18. Vaccine. 2011. PMID: 20600491 Review. No abstract available.
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses.
Wilkinson B, Patel KS, Smith K, Walker R, Wang C, Greene AM, Smith G, Smith ER, Gurwith M, Chen RT; Benefit-Risk Assessment of VAccines by TechnolOgy Working Group BRAVATO; (ex-V3SWG). Wilkinson B, et al. Among authors: gurwith m. Vaccine. 2023 Oct 26;41(45):6762-6773. doi: 10.1016/j.vaccine.2023.07.040. Epub 2023 Sep 20. Vaccine. 2023. PMID: 37739888 Free article.
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Medigen COVID-19 protein vaccine.
Estephan L, Liu LT, Lien CE, Smith ER, Gurwith M, Chen RT; Benefit-Risk Assessment of VAccines by TechnolOgy Working Group (BRAVATO ex-V3SWG). Estephan L, et al. Among authors: gurwith m. Vaccine. 2023 Apr 6;41(15):2615-2629. doi: 10.1016/j.vaccine.2023.02.083. Epub 2023 Mar 3. Vaccine. 2023. PMID: 36925422 Free PMC article.
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273).
Leav B, Straus W, White P, Leav A, Gaines T, Maggiacomo G, Kim D, Smith ER, Gurwith M, Chen RT; Benefit-Risk Assessment of VAccines by TechnolOgy Working Group BRAVATO ex-V3SWG. Leav B, et al. Among authors: gurwith m. Vaccine. 2022 Aug 19;40(35):5275-5293. doi: 10.1016/j.vaccine.2022.06.005. Epub 2022 Jun 9. Vaccine. 2022. PMID: 35753841 Free PMC article.
Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment.
Folegatti PM, Jenkin D, Morris S, Gilbert S, Kim D, Robertson JS, Smith ER, Martin E, Gurwith M, Chen RT; Benefit-Risk Assessment of VAccines by TechnolOgy Working Group BRAVATO, ex-V3SWG). Folegatti PM, et al. Among authors: gurwith m. Vaccine. 2022 Aug 19;40(35):5248-5262. doi: 10.1016/j.vaccine.2022.06.008. Epub 2022 Jun 14. Vaccine. 2022. PMID: 35715352 Free PMC article.
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for an inactivated viral vaccine against Chikungunya virus.
Hernandez LM, Sumathy K, Sahastrabuddhe S, Excler JL, Kochhar S, Smith ER, Gurwith M, Chen RT; Benefit-Risk Assessment of VAccines by TechnolOgy Working Group (BRAVATO, ex-V3SWG). Hernandez LM, et al. Among authors: gurwith m. Vaccine. 2022 Aug 19;40(35):5263-5274. doi: 10.1016/j.vaccine.2022.06.006. Epub 2022 Jun 15. Vaccine. 2022. PMID: 35715351 Free PMC article. Clinical Trial.
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for a soluble glycoprotein vaccine to prevent disease caused by Nipah or Hendra viruses.
Eldridge JH, Egan MA, Matassov D, Hamm S, Hermida L, Chen T, Tremblay M, Sciotto-Brown S, Xu R, Dimitrov A, Smith ER, Gurwith M, Chen RT; Benefit-Risk Assessment of VAccines by TechnolOgy Working Group BRAVATO, ex-V3SWG). Eldridge JH, et al. Among authors: gurwith m. Vaccine. 2021 Sep 7;39(38):5436-5441. doi: 10.1016/j.vaccine.2021.07.030. Epub 2021 Aug 7. Vaccine. 2021. PMID: 34373117 Free article. Review.
142 results